Table 3.
CRC patient-derived organoids—patient characteristics and IC50 of response to (−)-P, (+)-P and (R)-P.
| Sample | Sex | Age | Location | Stage | Primary/Metastasis | MMR * | IC50 (µM) | ||
|---|---|---|---|---|---|---|---|---|---|
| (−)-P | (+)-P | (R)-P | |||||||
| TQEH 196 | M | 59 | Liver | T4 | Metastasis | MSS | 3.23 | 3.82 | 4.76 |
| TQEH 198 | M | 68 | Liver | T4 | Metastasis | MSS | 1.36 | 2.87 | 3.78 |
| SAH01 | F | 50 | Lung | T4 | Metastasis | MSS | 1.23 | 1.36 | 1.95 |
| RAH038 | F | 87 | Colon (Ascending) | T3 | Primary | MSI (Absent MLH1 and PMS2) | 4.38 | 4.48 | 3.93 |
| RAH057 | F | 65 | Colon (Sigmoid) | T3 | Primary | MSS | 2.62 | 2.81 | 3.28 |
| RAP05 | M | 71 | Colon (Caecum) | T3 | Primary | MSS | 3.36 | 3.25 | 4.93 |
| RAH51 | F | 82 | Colon (Hepatic Flexure) | T4 | Primary | MSI (Absent MLH1 and PMS2) | 1.91 | 2.07 | 2.80 |
* Mismatch repair (MMR) status denoted either as: Microsatellite Stable (MSS) or Microsatellite Instable (MSI).